Identifying blood markers to predict treatment response in rectal cancer patients
Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer
This study is looking at how a new blood test can help doctors figure out which patients with locally advanced rectal cancer will respond well to their treatment before they start, so they can tailor the therapy to each person and avoid unnecessary side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11143949 on NIH RePORTER |
What this research studies
This research focuses on patients with locally advanced rectal cancer who are undergoing neoadjuvant chemoradiation therapy. The goal is to develop and validate a blood test that can predict how well a patient will respond to this treatment. By analyzing specific biomarkers in blood samples, researchers aim to determine which patients are likely to benefit from the therapy and which may not respond at all. This approach seeks to make treatment more personalized and effective, potentially sparing some patients from unnecessary side effects of ineffective treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with locally advanced rectal cancer who are scheduled to receive neoadjuvant chemoradiation therapy.
Not a fit: Patients with rectal cancer who are not receiving neoadjuvant chemoradiation therapy or those with early-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for rectal cancer patients, improving outcomes and reducing unnecessary treatments.
How similar studies have performed: Previous research has shown promise in using blood-based biomarkers for predicting treatment responses in various cancers, suggesting that this approach may be viable.
Where this research is happening
Philadelphia, United States
- Research Inst of Fox Chase Can Ctr — Philadelphia, United States (Active)
Researchers
- Principal investigator: Arora, Sanjeevani — Research Inst of Fox Chase Can Ctr
- Study coordinator: Arora, Sanjeevani
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.